Iterum Therapeutics (ITRM) vs. Its Competitors Head-To-Head Analysis

Iterum Therapeutics (NASDAQ:ITRM) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Iterum Therapeutics to related companies based on the strength of its institutional ownership, profitability, earnings, valuation, analyst recommendations, dividends and risk.

Risk & Volatility

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Iterum Therapeutics’ rivals have a beta of -0.05, suggesting that their average stock price is 105% less volatile than the S&P 500.

Earnings & Valuation

This table compares Iterum Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	-$24.77 million	-0.04
Iterum Therapeutics Competitors	$5.31 billion	$3.20 billion	555.02

Iterum Therapeutics’ rivals have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Iterum Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Iterum Therapeutics Competitors	7815	13779	25777	1035	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.03%. Given Iterum Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Iterum Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Iterum Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Iterum Therapeutics Competitors	-2,393.16%	-220.83%	-16.11%

Summary

Iterum Therapeutics rivals beat Iterum Therapeutics on 10 of the 13 factors compared.

About Iterum Therapeutics

Iterum Therapeutics plc (NASDAQ:ITRM) is an Ireland-based pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant bacteria. The company’s lead product is sulopenem, a penem-class antibiotic designed to provide activity against a broad range of pathogens. In 2024, the U.S. Food and Drug Administration approved Orlynvah, an oral combination of sulopenem etzadroxil and probenecid, for the treatment of uncomplicated urinary tract infections in adult women when alternative oral antibacterial treatments are not suitable.